Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin αv in Glioblastoma Cells

αvβ3 integrin expression increases elasticity in human melanoma cells

(2020) Leda Lacaria et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Fibronectin promotes tumor cells growth and drugs resistance through a CDC42‐YAP dependent signaling pathway in colorectal cancer

(2020) Yu Ye et al.   CELL BIOLOGY INTERNATIONAL

Tumor microenvironment is critical for the maintenance of cellular states found in primary glioblastomas.

(2020) Allison R Pine et al.   Cancer Discovery

Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features

(2020) Hyeon Ji Kim et al.   MOLECULES

Balancing and Differentiating p53 Activities toward Longevity and No Cancer?

(2020) Izumi Horikawa   CANCER RESEARCH

Targeting PI3K Signaling in Acute Lymphoblastic Leukemia

(2019) Vanessa Sanchez et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Aberrations in DNA repair pathways in cancer and therapeutic significances

(2019) Akira Motegi et al.   SEMINARS IN CANCER BIOLOGY

Maslinic acid alleviates ischemia/reperfusion-induced inflammation by downregulation of NFκB-mediated adhesion molecule expression

(2019) Emmanuel Ampofo et al.   Scientific Reports

miR-182 contributes to cell adhesion-mediated drug resistance in multiple myeloma via targeting PDCD4

(2019) Yaxun Wu et al.   PATHOLOGY RESEARCH AND PRACTICE

Laminin-Inspired Cell-Instructive Microenvironments for Neural Stem Cells

(2019) Daniela Barros et al.   BIOMACROMOLECULES

Laminins in Cellular Differentiation

(2019) Lynn Yap et al.   TRENDS IN CELL BIOLOGY

CD44 collaborates with ERBB2 mediate radiation resistance via p38 phosphorylation and DNA homologous recombination pathway in prostate cancer

(2018) Ji-wei Ma et al.   EXPERIMENTAL CELL RESEARCH

Fibronectin Promotes the Malignancy of Glioma Stem-Like Cells Via Modulation of Cell Adhesion, Differentiation, Proliferation and Chemoresistance

(2018) Qi Yu et al.   Frontiers in Molecular Neuroscience

Dynamic perspectives into the mechanisms of mutation-induced p53-DNA binding loss and inactivation using active perturbation theory: Structural and molecular insights toward the design of potent reactivators in cancer therapy

(2018) Fisayo. A. Olotu et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

The Influence of Metabolism on Drug Response in Cancer

(2018) Esther A. Zaal et al.   Frontiers in Oncology

Breaching barriers in glioblastoma. Part I: Molecular pathways and novel treatment approaches

(2017) Ana Miranda et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin

(2017) Fengbin Gao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Problems of glioblastoma multiforme drug resistance

(2016) A. A. Stavrovskaya et al.   BIOCHEMISTRY-MOSCOW

Nanoparticles: Novel vehicles in treatment of Glioblastoma

(2016) Fatemeh Pourgholi et al.   BIOMEDICINE & PHARMACOTHERAPY

Glioma cell dispersion is driven by α5 integrin-mediated cell–matrix and cell–cell interactions

(2016) Anne-Florence Blandin et al.   CANCER LETTERS

Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor- B Signaling for Cancer Treatment

(2016) K. P. Zeligs et al.   CLINICAL CANCER RESEARCH

Dynamic transcription factor activity networks in response to independently altered mechanical and adhesive microenvironmental cues

(2016) Beatriz Peñalver Bernabé et al.   Integrative Biology

Targeting autophagy to sensitive glioma to temozolomide treatment

(2016) Yuanliang Yan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial

(2016) Mustafa Khasraw et al.   JOURNAL OF NEURO-ONCOLOGY

Large-scale assessment of the gliomasphere model system

(2016) Dan R. Laks et al.   NEURO-ONCOLOGY

High expression of fibronectin is associated with poor prognosis, cell proliferation and malignancy via the NF-κB/p53-apoptosis signaling pathway in colorectal cancer

(2016) Wenzhong Yi et al.   ONCOLOGY REPORTS

Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review

(2016) Lynn S. Ashby et al.   World Journal of Surgical Oncology

Glioblastomas Require Integrin αvβ3/PAK4 Signaling to Escape Senescence

(2015) Aleksandra Franovic et al.   CANCER RESEARCH

Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide

(2015) Khaled Messaoudi et al.   DRUG DISCOVERY TODAY

Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis

(2015) Sajeel A. Chowdhary et al.   JOURNAL OF NEURO-ONCOLOGY

MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

(2015) L. R. Kong et al.   MOLECULAR CANCER THERAPEUTICS

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

(2015) L. Burt Nabors et al.   NEURO-ONCOLOGY

Novel delivery methods bypassing the blood-brain and blood-tumor barriers

(2015) Benjamin K. Hendricks et al.   Neurosurgical Focus

Focal adhesion signaling and therapy resistance in cancer

(2015) Iris Eke et al.   SEMINARS IN CANCER BIOLOGY

Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme

(2015) Amanda Tivnan et al.   Frontiers in Neuroscience

Disruption of integrin–fibronectin complexes by allosteric but not ligand-mimetic inhibitors

(2014) A. Paul Mould et al.   BIOCHEMICAL JOURNAL

Overexpression of integrin αv facilitates proliferation and invasion of oral squamous cell carcinoma cells via MEK/ERK signaling pathway that is activated by interaction of integrin αvβ8 with type I collagen

(2014) YASUTAKA HAYASHIDO et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Overexpression of fibronectin confers cell adhesion-mediated drug resistance (CAM-DR) against 5-FU in oral squamous cell carcinoma cells

(2014) YOSHIHIRO NAKAGAWA et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

The Role of Integrin αv in Proliferation and Differentiation of Human Dental Pulp Cell Response to Calcium Silicate Cement

(2014) Chi-Jr Hung et al.   JOURNAL OF ENDODONTICS

Glioblastoma: Background, Standard Treatment Paradigms, and Supportive Care Considerations

(2014) Susan V. Ellor et al.   JOURNAL OF LAW MEDICINE & ETHICS

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

Temozolomide Induces the Production of Epidermal Growth Factor to Regulate MDR1 Expression in Glioblastoma Cells

(2014) J. L. Munoz et al.   MOLECULAR CANCER THERAPEUTICS

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gastric cancer cell adhesion to laminin enhances acquired chemotherapeutic drug resistance mediated by MGr1-Ag/37LRP

(2014) LI SUN et al.   ONCOLOGY REPORTS

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy

(2014) Mira Patel et al.   Cancers

Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells

(2013) Qing-Zhi Long et al.   ANTI-CANCER DRUGS

Adhesion to fibronectin induces p27Kip1 nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells

(2013) Min Fei et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status

(2013) Niklas Thon et al.   OncoTargets and Therapy

De-Repression of PDGFRβ Transcription Promotes Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma Patients

(2013) David Akhavan et al.   Cancer Discovery

Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance

(2012) T. E. Taylor et al.   CURRENT CANCER DRUG TARGETS

The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review

(2011) Sanjay Dixit et al.   BRITISH JOURNAL OF NEUROSURGERY

Glioblastoma Angiogenesis and Tumor Cell Invasiveness Are Differentially Regulated by  8 Integrin

(2011) J. H. Tchaicha et al.   CANCER RESEARCH

Involvement of the TGFβ pathway in the regulation of α5β1 integrins by caveolin-1 in human glioblastoma

(2011) Erika C. Cosset et al.   INTERNATIONAL JOURNAL OF CANCER

Cellular arrays for large-scale analysis of transcription factor activity

(2010) Abigail D. Bellis et al.   BIOTECHNOLOGY AND BIOENGINEERING

Integrin Alpha 6: Anchors Away for Glioma Stem Cells

(2010) Nina S. Corsini et al.   Cell Stem Cell

Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy

(2009) Mary Lou Affronti et al.   CANCER

Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma Patients

(2009) K. V. Lu et al.   CANCER RESEARCH

EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy

(2009) D. Guo et al.   Science Signaling

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY